MD Anderson establishes new $50M+ biotech fund to choose the next promising cancer therapies

Researchers at MD Anderson have a new partner to help them get early-stage programs into the clinic.

In conjunction with The Focus Fund, a global mutual fund run by investment management firm Neuberger Berman, MD Anderson is launching the Cancer Focus Fund to advance investigational cancer therapies from late preclinical development through Phase I and Phase Ib/II clinical trials. The fund will start off with more than $50 million of initial capital.